Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-cell receptor signaling. Further trials also suggest that ...
Feb 28, 2020
0
3
Walter and Eliza Hall Institute researchers have revealed a new vulnerability in lymphomas that are driven by one of the most common cancer-causing changes in cells.
Feb 20, 2020
0
8
(HealthDay)—Adolescent and young adult (AYA) cancer survivors (aged 15 to 39 years) have an increased risk for inpatient hospitalization, according to a study published online Jan. 20 in Cancer Epidemiology, Biomarkers ...
Feb 12, 2020
0
1
Walter and Eliza Hall Institute researchers have narrowed the focus on which survival proteins are important for the survival of B cell lymphomas, eliminating the protein BCL-W from the "suspect list."
Feb 5, 2020
0
31
(HealthDay)—Nitrite consumption is associated with an increased risk for non-Hodgkin lymphoma (NHL), according to a meta-analysis published online Jan. 17 in Scientific Reports.
Jan 30, 2020
0
1
A hormone therapy will now be available for some people with newly diagnosed, advanced prostate cancer in Scotland for the first time.
Jan 21, 2020
0
1
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response ...
Jan 8, 2020
0
15
(HealthDay)—Among children with Hodgkin lymphoma (HL) enrolled in phase III trials, nonwhite patients have an increased risk for death, according to a study published in the Nov. 10 issue of the Journal of Clinical Oncology.
Dec 12, 2019
0
3
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric ...
Dec 9, 2019
0
5
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients ...
Dec 9, 2019
0
2
